Nuclera was at the University of Southampton on January 9th to install the eProtein Discovery™ system. It is Nuclera’s first system installation, thus generating a lot of excitement for both the company and the university. Haren Arulanantham (Director of Global Applications, Nuclera) and Chiara Gandini (Field Application Scientist in BD & Sales, Nuclera) were on hand to assist Professor Hywel Morgan (University of Southampton, School of Electronics and Computer Science) to guide him in his early days with his lab’s newly acquired eProtein Discovery™ system.
Professor Morgan joined Nuclera as a Scientific Advisor in 2018. He is Professor of Bioelectronics at the University of Southampton and specializes in biosensors, nanotechnology and lab-on-a-chip technologies. Professor Morgan is also the co-founder of medical device companies Verso Biosense and iFAST Diagnostics.
The eProtein Discovery™ system is already in the hands of Professor Hywel Morgan at the University of Southampton in previous editions, initially to demonstrate the proof of concept in October 2020.
October 2020 – Prof Hywel pipettes reagents into a nascent version of eProtein Discovery, ‘Big Blue’
In August 2022, Nuclera provided Professor Morgan with the eProtein Discovery System as part of Nuclera’s early adoption trial, which was used to gather valuable customer feedback as part of product development.
August 2022 – first prototype demonstration at Southampton University
Following the success of the trial in late 2022, the University of Southampton has moved to acquire the eProtein Discovery System on a permanent basis, which will be used to explore proteins such as the COVID Ace2 inhibitor protein among others.
Their previous attempts to express the COVID Ace2 inhibitor using conventional techniques had proved unsuccessful, which was one of the reasons why the lab decided to use eProtein Discovery in the 2022 early adopter trial to be able to express it protein for the first time. Ultimately this success led the lab to commit to purchasing the fully launched system.
January 2023 – first development of the commercial version of the eProtein Discovery System in Professor Morgan’s lab, University of Southampton
Professor Hywel commented “[the installation] it went well and I must congratulate everyone for the very significant improvement of the machine!”
“eProtein Discovery by Nuclera leverages artificial intelligence and microfluidics to rapidly optimize recombinant protein production, revolutionizing current pipelines.
The installation of eProtein Discovery at the University of Southampton is the culmination of a close development partnership which will continue with the continued support of Nuclera to ensure that Professor Morgan’s research group benefits from all that the Nuclera system has to offer.
“Nuclera is excited to deliver the eProtein Discovery System as a finished product to the University of Southampton, the first customer delivery of its kind!” said Dr. Michael Chen, CEO of Nuclera.
“We want to thank Professor Morgan’s lab for being part of the development journey, his and his colleagues’ input has been invaluable in making our system a reality for him and other customers who need protein prototypes.”
Dr. Michael Chen, CEO of Nuclera;
